NLSP

NLS Pharmaceutics Ltd (NLSP) | Rumor.io

NLS Pharmaceutics

NLSP

Attention (50-day avg)0%

Attention rank (50-day avg)#4,484

Bullish sentiment (50-day avg)100%

Price to earnings ratio0

Market capitalization15.3M

Earnings per share-17.4

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-4.1M

Social

What share of all stock conversation is about NLSP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% new	0% 0

Mar 4

Analyst sets target price for NLS Pharmaceutics AG (NLSP) for next week.
Analyst sets target price for NLS Pharmaceutics AG (NLSP) for today.
No additional market-relevant information is available.

Generated by AI

Sentiment

Of the messages about NLSP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	91.12% -4.09
Bearish	—	—	—	8.88% +4.09

Sep 30

$NLSP has shown explosive growth momentum, with a +70% increase, and is moving forward with its Kadimastem merger, expanding into ALS, diabetes, and CNS.
The company has secured $2M in equity financing with an option for an additional $1M, and has been granted a new Hong Kong patent, strengthening its position.
$NLSP has a low float and a high probability of further growth, with projected returns of 10-26% and a recent rebound of +50% from earlier lows.

Generated by AI

Topics

Of the messages about NLSP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	99.23%
Analysts	—	0%	0%	0%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	0%
Technical Analysis	—	0%	0%	0.77%

Announcements· Oct 29

NLS Pharmaceutics AG announced a 1-for-10 reverse share split and name change in connection with the proposed merger with Kadimastem.
The company's shares will trade under the new symbol NCEL on NASDAQ, following the completion of the merger and delisting of Kadimastem's shares.
The merger is expected to result in the development of a new treatment for type 1 diabetes using ITOL-102, a program supported by the BIRD Foundation.

Technical Analysis· Mar 12

NLSP's price action bears a strong resemblance to a prior event, which is being closely monitored.
$NLSP's trading volume has been extremely high, similar to that of $EYES.
Investors are taking note of NLSP's price movement as the day nears its close.

Generated by AI

Community

Of the messages about NLSP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	50%	83.33%	40.05%
Newcomers	—	50%	16.67%	59.95%

Regulars· Sep 30

NLS Pharmaceutics shareholders have approved a merger with Kadimastem, with Kadimastem shareholders set to own 84.4% of the combined company, NewCelX Ltd.
The merger is expected to bring together expertise in cell therapy and CNS drugs, with the combined company set to be renamed NewCelX Ltd. and trade under a new ticker $NCEL.
The merger has been approved by NLS Pharmaceutics shareholders, with the company's shareholders approving related proposals at an extraordinary general meeting.

Newcomers· Oct 31

The merger between NLS Pharmaceutics AG and Kadimastem has resulted in a new company called NewceX, with the stock ticker changing to $NCEL, and the stock price experiencing a significant spike of nearly 50%.
The reverse split of 1-for-10 has affected the stock price, with some users wondering why the price is not reflecting the correct value after the split, and others discussing the potential for a "squeeze" on the new ticker $NCEL.
The merger and reverse split have resulted in some users having separate shares of the new company, but not knowing what to do with the shares that have not converted, and others discussing the low float and delayed exchange data affecting the stock price.

Generated by AI

Also Discussed

Investors talking about NLSP also mention

#	Name	Attention
1	Entera Bio Ltd.ENTX	0%new
2	CFSB - CFSB Bancorp, Inc.	——
3	PTL Limited Class A Ordinary SharesPTLE	0%new
4	Brenmiller Energy LtdBNRG	0%new
5	BSFC - Blue Star Foods Corp.	——
6	Tuhura Biosciences Inc.KTRA	0%new
7	APCX - AppTech Payments Corp.	——
8	LIPO - Lipella Pharmaceuticals Inc.	——
9	Northann Corp.NCL	0%0
10	Bluejay Diagnostics Inc.BJDX	0%0

NLS Pharmaceutics Ltd

Healthcare
Biotechnology

NLS Pharmaceutics Ltd is a biopharmaceutical company focused on the discovery and development of innovative therapies for the treatment of rare and complex central nervous system disorders. The company's primary purpose is to address unmet medical needs by advancing a robust pipeline of drug candidates through clinical trials and regulatory innovations. NLS Pharmaceutics operates in the biotechnology sector with an emphasis on neuroscience, specifically targeting conditions such as narcolepsy, ADHD, and excessive daytime sleepiness. Headquartered in Switzerland, NLS Pharmaceutics leverages scientific expertise and cutting-edge research to develop its proprietary compounds. The company's flagship projects include promising drug candidates which aim to revolutionize therapies for conditions that currently have limited treatment options. Market-wise, NLS Pharmaceutics plays a significant role by potentially introducing breakthrough treatments that could enhance the quality of life for patients while entering a growing pharmaceutical landscape. The company's commitment to addressing both efficacy and safety in its medication portfolio positions it as a noteworthy entity among stakeholders within the global biopharmaceutical industry.

Website

Location

The Circle 6

Zurich, 8058

Switzerland

Social

What share of all stock conversation is about NLSP?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% new	0% 0

Mar 4

Analyst sets target price for NLS Pharmaceutics AG (NLSP) for next week.
Analyst sets target price for NLS Pharmaceutics AG (NLSP) for today.
No additional market-relevant information is available.

Generated by AI

Sentiment

Of the messages about NLSP that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	91.12% -4.09
Bearish	—	—	—	8.88% +4.09

Sep 30

$NLSP has shown explosive growth momentum, with a +70% increase, and is moving forward with its Kadimastem merger, expanding into ALS, diabetes, and CNS.
The company has secured $2M in equity financing with an option for an additional $1M, and has been granted a new Hong Kong patent, strengthening its position.
$NLSP has a low float and a high probability of further growth, with projected returns of 10-26% and a recent rebound of +50% from earlier lows.

Generated by AI

Topics

Of the messages about NLSP that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	99.23%
Analysts	—	0%	0%	0%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	0%
Technical Analysis	—	0%	0%	0.77%

Announcements· Oct 29

NLS Pharmaceutics AG announced a 1-for-10 reverse share split and name change in connection with the proposed merger with Kadimastem.
The company's shares will trade under the new symbol NCEL on NASDAQ, following the completion of the merger and delisting of Kadimastem's shares.
The merger is expected to result in the development of a new treatment for type 1 diabetes using ITOL-102, a program supported by the BIRD Foundation.

Technical Analysis· Mar 12

NLSP's price action bears a strong resemblance to a prior event, which is being closely monitored.
$NLSP's trading volume has been extremely high, similar to that of $EYES.
Investors are taking note of NLSP's price movement as the day nears its close.

Generated by AI

Community

Of the messages about NLSP, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	50%	83.33%	40.05%
Newcomers	—	50%	16.67%	59.95%

Regulars· Sep 30

NLS Pharmaceutics shareholders have approved a merger with Kadimastem, with Kadimastem shareholders set to own 84.4% of the combined company, NewCelX Ltd.
The merger is expected to bring together expertise in cell therapy and CNS drugs, with the combined company set to be renamed NewCelX Ltd. and trade under a new ticker $NCEL.
The merger has been approved by NLS Pharmaceutics shareholders, with the company's shareholders approving related proposals at an extraordinary general meeting.

Newcomers· Oct 31

The merger between NLS Pharmaceutics AG and Kadimastem has resulted in a new company called NewceX, with the stock ticker changing to $NCEL, and the stock price experiencing a significant spike of nearly 50%.
The reverse split of 1-for-10 has affected the stock price, with some users wondering why the price is not reflecting the correct value after the split, and others discussing the potential for a "squeeze" on the new ticker $NCEL.
The merger and reverse split have resulted in some users having separate shares of the new company, but not knowing what to do with the shares that have not converted, and others discussing the low float and delayed exchange data affecting the stock price.

Generated by AI

NLS Pharmaceutics

Social

Mar 4

Sentiment

Sep 30

Topics

Announcements· Oct 29

Technical Analysis· Mar 12

Community

Regulars· Sep 30

Newcomers· Oct 31

Also Discussed

NLS Pharmaceutics Ltd

Company Information

Location

Also Discussed

Social

Mar 4

Sentiment

Sep 30

Topics

Announcements· Oct 29

Technical Analysis· Mar 12

Community

Regulars· Sep 30

Newcomers· Oct 31